Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celebrex in Recurrent Respiratory Papillomatosis
NCT00571701Phase 2Completed
- Sponsor
- Northwell Health
- Start
- Feb 2008
- Primary completion
- Jan 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in recurrent respiratory papillomatosis (RRP) comparing Celecoxib First with Placebo First (2 arms). Primary endpoint: Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline. Started Feb 2008; status: completed.
02
Drugs
celecoxib
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT00571701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571701.